Scientists probe Glucagon's role in liver health and diabetes
NCT ID NCT05500586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the hormone glucagon affects the liver's ability to break down proteins and fats in people with obesity, type 2 diabetes, and fatty liver disease. Researchers wanted to understand if the body becomes resistant to glucagon in these conditions. A total of 21 participants completed the study, which involved measuring amino acid clearance with and without glucagon.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- A new rice could tame blood sugar spikes in prediabetes
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?